Zacks Investment Research upgraded shares of Avinger (NASDAQ:AVGR) from a hold rating to a buy rating in a research report sent to investors on Wednesday morning. Zacks Investment Research currently has $0.25 price objective on the medical device company’s stock.
According to Zacks, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California. “
Shares of Avinger (NASDAQ:AVGR) opened at $0.20 on Wednesday. Avinger has a 12-month low of $0.17 and a 12-month high of $3.66.
A hedge fund recently bought a new stake in Avinger stock. AWM Investment Company Inc. bought a new position in shares of Avinger Inc (NASDAQ:AVGR) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,150,000 shares of the medical device company’s stock, valued at approximately $516,000. AWM Investment Company Inc. owned 4.81% of Avinger as of its most recent SEC filing. Institutional investors own 3.79% of the company’s stock.
WARNING: “Avinger (AVGR) Upgraded at Zacks Investment Research” was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.com-unik.info/2018/01/06/avinger-avgr-upgraded-at-zacks-investment-research.html.
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Avinger? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Avinger and related companies.